PEGBIO CO-B (02565) surged over 5% in morning trading, with the stock having gained over 3.1 times since its listing. As of press time, the stock was up 5.25% to HK$54.15, with a trading volume of HK$19.8656 million.

A research report highlighted that the global GLP-1 drug market is dominated by Novo Nordisk and Eli Lilly, while other multinational corporations (MNCs) are accelerating their market positioning. With continuous expansion of indications, improvement of dosage forms, and iterative optimization of therapeutic effects, the broader GLP-1 track is viewed as having significant growth potential from both potential patient base and market scale perspectives, representing the most important track for MNCs in the metabolic chronic disease field.

Meanwhile, some MNCs still have considerable room for improvement in their GLP-1 field strategies regarding technical pathways, new targets, and new indications, creating optimistic prospects for domestic niche pharmaceutical companies' overseas business development opportunities.

The analysis suggests that some domestic pipelines in the GLP-1 multi-target field have advanced clinical progress and are expected to continue generating significant business development events.

PB-718 is a blockbuster product in PEGBIO's pipeline. The drug is a novel long-acting GLP-1/GCG dual receptor agonist with its core therapeutic focus on MASH (Metabolic dysfunction-Associated Steatohepatitis) treatment. PEGBIO's disclosed Phase Ib/IIa clinical trial results for PB-718 showed that after dose titration, the 1.6mg dose of PB-718 treatment for 18 weeks significantly reduced liver fat content, with a mean percentage change from baseline of -57.14% and a maximum reduction of 62%. This achieved more significant liver fat reduction in a shorter treatment period compared to semaglutide.